# Sonoma Pharmaceuticals, Inc.: financial statements, quarterly

SNOA · Nasdaq · CIK 1367083 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/snoa.md) · [Financials](/companies/snoa/financials.md) · [Filings](/companies/snoa/filings.md) · [Insiders](/companies/snoa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/snoa/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,731](/filings/0001683168-24-007708.md) | [3,138](/filings/0001683168-25-000736.md) | [3,439 d](/filings/0001683168-25-004546.md) | [3,391](/filings/0001683168-25-005753.md) | [3,579](/filings/0001683168-25-007938.md) | [3,564](/filings/0001683168-26-000889.md) | [3,754 d](/filings/0001683168-26-004871.md) | [4,015](/filings/0001683168-26-006024.md) | [5,604](/filings/0001683168-25-007938.md) | [4,349](/filings/0001683168-26-000889.md) | [5,561 d](/filings/0001683168-26-004871.md) | [6,406](/filings/0001683168-26-006024.md) |
| Cost of revenue | $k | [1,741](/filings/0001683168-24-007708.md) | [1,678](/filings/0001683168-25-000736.md) | [2,348 d](/filings/0001683168-25-004546.md) | [2,085](/filings/0001683168-25-005753.md) | [2,218](/filings/0001683168-25-007938.md) | [2,294](/filings/0001683168-26-000889.md) | [2,226 d](/filings/0001683168-26-004871.md) | [2,551](/filings/0001683168-26-006024.md) | [3,484](/filings/0001683168-25-007938.md) | [2,699](/filings/0001683168-26-000889.md) | [3,380 d](/filings/0001683168-26-004871.md) | [3,829](/filings/0001683168-26-006024.md) |
| Gross profit | $k | [990](/filings/0001683168-24-007708.md) | [1,460](/filings/0001683168-25-000736.md) | [1,091 d](/filings/0001683168-25-004546.md) | [1,306](/filings/0001683168-25-005753.md) | [1,361](/filings/0001683168-25-007938.md) | [1,270](/filings/0001683168-26-000889.md) | [1,528 d](/filings/0001683168-26-004871.md) | [1,464](/filings/0001683168-26-006024.md) | [2,120](/filings/0001683168-25-007938.md) | [1,650](/filings/0001683168-26-000889.md) | [2,181 d](/filings/0001683168-26-004871.md) | [2,577](/filings/0001683168-26-006024.md) |
| Research and development | $k | [536](/filings/0001683168-24-007708.md) | [601](/filings/0001683168-25-000736.md) | [409 d](/filings/0001683168-25-004546.md) | [470](/filings/0001683168-25-005753.md) | [506](/filings/0001683168-25-007938.md) | [427](/filings/0001683168-26-000889.md) | [411 d](/filings/0001683168-26-004871.md) | [594](/filings/0001683168-26-006024.md) | [575](/filings/0001683168-25-007938.md) | [557](/filings/0001683168-26-000889.md) | [545 d](/filings/0001683168-26-004871.md) | [597](/filings/0001683168-26-006024.md) |
| Selling, general and administrative | $k | [1,662](/filings/0001683168-24-007708.md) | [1,703](/filings/0001683168-25-000736.md) | [2,091 d](/filings/0001683168-25-004546.md) | [2,009](/filings/0001683168-25-005753.md) | [1,705](/filings/0001683168-25-007938.md) | [1,874](/filings/0001683168-26-000889.md) | [1,773 d](/filings/0001683168-26-004871.md) | [1,965](/filings/0001683168-26-006024.md) | [1,882](/filings/0001683168-25-007938.md) | [1,771](/filings/0001683168-26-000889.md) | [1,987 d](/filings/0001683168-26-004871.md) | [2,020](/filings/0001683168-26-006024.md) |
| Operating income | $k | [(1,208)](/filings/0001683168-24-007708.md) | [(844)](/filings/0001683168-25-000736.md) | [(1,409) d](/filings/0001683168-25-004546.md) | [(1,173)](/filings/0001683168-25-005753.md) | [(850)](/filings/0001683168-25-007938.md) | [(1,031)](/filings/0001683168-26-000889.md) | [(656) d](/filings/0001683168-26-004871.md) | [(1,095)](/filings/0001683168-26-006024.md) | [(337)](/filings/0001683168-25-007938.md) | [(678)](/filings/0001683168-26-000889.md) | [(351) d](/filings/0001683168-26-004871.md) | [(40.0)](/filings/0001683168-26-006024.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [186](/filings/0001683168-24-007708.md) | [(57.0)](/filings/0001683168-25-000736.md) | [(292) d](/filings/0001683168-25-004546.md) | [146](/filings/0001683168-25-005753.md) | [147](/filings/0001683168-25-007938.md) | [9.0](/filings/0001683168-26-000889.md) | [248 d](/filings/0001683168-26-004871.md) | [(1.0)](/filings/0001683168-26-006024.md) | [(197)](/filings/0001683168-25-007938.md) | [(130)](/filings/0001683168-26-000889.md) | [84.0 d](/filings/0001683168-26-004871.md) | [0.0](/filings/0001683168-26-006024.md) |
| Net income | $k | [(1,484)](/filings/0001683168-25-000736.md) | [(866)](/filings/0001683168-25-000736.md) | [(1,067) d](/filings/0001683168-25-004546.md) | [(1,143)](/filings/0001683168-26-000889.md) | [(610)](/filings/0001683168-26-000889.md) | [(928)](/filings/0001683168-26-000889.md) | [(776) d](/filings/0001683168-26-004871.md) | [(1,241)](/filings/0001683168-26-006024.md) | [(534)](/filings/0001683168-26-000889.md) | [(819)](/filings/0001683168-26-000889.md) | [(581) d](/filings/0001683168-26-004871.md) | [(330)](/filings/0001683168-26-006024.md) |
| Diluted EPS | $ per share | [(5.75)](/filings/0001683168-24-007708.md) | [(1.59)](/filings/0001683168-25-000736.md) | not reported | [(1.34)](/filings/0001683168-25-005753.md) | [(0.59)](/filings/0001683168-25-007938.md) | [(0.63)](/filings/0001683168-26-000889.md) | not reported | [(0.76)](/filings/0001683168-26-006024.md) | [(0.32)](/filings/0001683168-25-007938.md) | [(0.48)](/filings/0001683168-26-000889.md) | not reported | [(0.09)](/filings/0001683168-26-006024.md) |
| Basic EPS | $ per share | [(5.75)](/filings/0001683168-24-007708.md) | [(1.59)](/filings/0001683168-25-000736.md) | not reported | [(1.34)](/filings/0001683168-25-005753.md) | [(0.59)](/filings/0001683168-25-007938.md) | [(0.63)](/filings/0001683168-26-000889.md) | not reported | [(0.76)](/filings/0001683168-26-006024.md) | [(0.32)](/filings/0001683168-25-007938.md) | [(0.48)](/filings/0001683168-26-000889.md) | not reported | [(0.09)](/filings/0001683168-26-006024.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.1](/filings/0001683168-23-007982.md) | [2.4](/filings/0001683168-24-000781.md) | [3.1](/filings/0001683168-25-004546.md) | [2.6](/filings/0001683168-24-005371.md) | [4.1](/filings/0001683168-24-007708.md) | [5.2](/filings/0001683168-25-000736.md) | [5.4](/filings/0001683168-26-004871.md) | [3.6](/filings/0001683168-25-005753.md) | [3.0](/filings/0001683168-25-007938.md) | [2.6](/filings/0001683168-26-000889.md) | [2.4](/filings/0001683168-26-006024.md) | [5.3](/filings/0001683168-26-006024.md) |
| Current assets | $m | [11.5](/filings/0001683168-23-007982.md) | [12.5](/filings/0001683168-24-000781.md) | [12.5](/filings/0001683168-25-004546.md) | [11.9](/filings/0001683168-24-005371.md) | [12.2](/filings/0001683168-24-007708.md) | [12.4](/filings/0001683168-25-000736.md) | [12.6](/filings/0001683168-26-004871.md) | [13.1](/filings/0001683168-25-005753.md) | [12.5](/filings/0001683168-25-007938.md) | [12.1](/filings/0001683168-26-000889.md) | [12.1](/filings/0001683168-26-006024.md) | [16.3](/filings/0001683168-26-006024.md) |
| Total assets | $m | [13.6](/filings/0001683168-23-007982.md) | [14.6](/filings/0001683168-24-000781.md) | [14.7](/filings/0001683168-25-004546.md) | [13.7](/filings/0001683168-24-005371.md) | [13.7](/filings/0001683168-24-007708.md) | [13.7](/filings/0001683168-25-000736.md) | [13.7](/filings/0001683168-26-004871.md) | [14.6](/filings/0001683168-25-005753.md) | [13.9](/filings/0001683168-25-007938.md) | [13.6](/filings/0001683168-26-000889.md) | [14.0](/filings/0001683168-26-006024.md) | [18.1](/filings/0001683168-26-006024.md) |
| Current liabilities | $m | [3.2](/filings/0001683168-23-007982.md) | [3.1](/filings/0001683168-24-000781.md) | [3.7](/filings/0001683168-25-004546.md) | [3.8](/filings/0001683168-24-005371.md) | [3.3](/filings/0001683168-24-007708.md) | [3.7](/filings/0001683168-25-000736.md) | [4.1](/filings/0001683168-26-004871.md) | [4.8](/filings/0001683168-25-005753.md) | [4.3](/filings/0001683168-25-007938.md) | [4.2](/filings/0001683168-26-000889.md) | [4.8](/filings/0001683168-26-006024.md) | [5.4](/filings/0001683168-26-006024.md) |
| Total liabilities | $m | [8.0](/filings/0001683168-23-007982.md) | [7.9](/filings/0001683168-24-000781.md) | [8.6](/filings/0001683168-25-004546.md) | [8.7](/filings/0001683168-24-005371.md) | [8.3](/filings/0001683168-24-007708.md) | [8.8](/filings/0001683168-25-000736.md) | [9.3](/filings/0001683168-26-004871.md) | [10.5](/filings/0001683168-25-005753.md) | [10.1](/filings/0001683168-25-007938.md) | [10.2](/filings/0001683168-26-000889.md) | [10.9](/filings/0001683168-26-006024.md) | [11.5](/filings/0001683168-26-006024.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | [0.3](/filings/0001683168-25-004546.md) | [0.2](/filings/0001683168-24-005371.md) | [0.1](/filings/0001683168-24-007708.md) | [0.0](/filings/0001683168-25-000736.md) | [0.2](/filings/0001683168-26-004871.md) | [0.1](/filings/0001683168-25-005753.md) | [0.1](/filings/0001683168-25-007938.md) | [0.0](/filings/0001683168-26-000889.md) | [0.2](/filings/0001683168-26-006024.md) | [0.1](/filings/0001683168-26-006024.md) |
| Shareholders' equity | $m | [5.7](/filings/0001683168-25-000736.md) | [6.7](/filings/0001683168-25-000736.md) | [6.1](/filings/0001683168-26-004871.md) | [5.0](/filings/0001683168-26-000889.md) | [5.4](/filings/0001683168-26-000889.md) | [4.9](/filings/0001683168-26-000889.md) | [4.4](/filings/0001683168-26-006024.md) | [4.1](/filings/0001683168-26-006024.md) | [3.8](/filings/0001683168-26-000889.md) | [3.4](/filings/0001683168-26-000889.md) | [3.1](/filings/0001683168-26-006024.md) | [6.6](/filings/0001683168-26-006024.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,231) d](/filings/0001683168-24-007708.md) | [(1,104) d](/filings/0001683168-25-000736.md) | [152 d](/filings/0001683168-25-004546.md) | [(912)](/filings/0001683168-25-005753.md) | [354 d](/filings/0001683168-25-007938.md) | [565 d](/filings/0001683168-26-000889.md) | [(95.0) d](/filings/0001683168-26-004871.md) | [(2,015)](/filings/0001683168-26-006024.md) | [(635) d](/filings/0001683168-25-007938.md) | [(764) d](/filings/0001683168-26-000889.md) | [(519) d](/filings/0001683168-26-004871.md) | [(649)](/filings/0001683168-26-006024.md) |
| Capital expenditure | $k | [2.0 d](/filings/0001683168-24-007708.md) | [1.0 d](/filings/0001683168-25-000736.md) | [(18.0) d](/filings/0001683168-25-004546.md) | [5.0](/filings/0001683168-25-005753.md) | [26.0 d](/filings/0001683168-25-007938.md) | [2.0 d](/filings/0001683168-26-000889.md) | [47.0 d](/filings/0001683168-26-004871.md) | [106](/filings/0001683168-26-006024.md) | [10.0 d](/filings/0001683168-25-007938.md) | [47.0 d](/filings/0001683168-26-000889.md) | [29.0 d](/filings/0001683168-26-004871.md) | [2.0](/filings/0001683168-26-006024.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3.1](/filings/0001683168-23-007982.md) | [3,107](/filings/0001683168-24-000781.md) | [4,936](/filings/0001683168-24-005371.md) | [258](/filings/0001683168-24-007708.md) | [546](/filings/0001683168-25-000736.md) | [851](/filings/0001683168-25-005753.md) | [1,034](/filings/0001683168-25-007938.md) | [1,464](/filings/0001683168-26-000889.md) | [1,641](/filings/0001683168-26-006024.md) | [1,646](/filings/0001683168-25-007938.md) | [1,713](/filings/0001683168-26-000889.md) | [3,846](/filings/0001683168-26-006024.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,788,425 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001683168-26-006024.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.